Remdesivir: a real turning point against COVID-19?

By Ana Espino | Published on May 12, 2026 | 4 min read


COVID-19 is a respiratory infection caused by SARS-CoV-2, responsible for a global pandemic that led to millions of hospitalizations and deaths. Severe forms of the disease can cause significant pneumonia, acute respiratory failure, and may require oxygen therapy or mechanical ventilation.

At the beginning of the pandemic, very few effective treatments were available against SARS-CoV-2, and patient management relied mainly on supportive care. Remdesivir, an antiviral initially developed against Ebola, was quickly identified as a potential candidate because of its action on viral replication. However, its actual effectiveness in hospitalized patients remained uncertain.

The main challenge was to determine whether an antiviral such as remdesivir could truly improve the clinical course of patients already hospitalized for COVID-19, and to identify at which stage of the disease it would be most effective, particularly in patients requiring oxygen therapy or mechanical ventilation. The aim of the study was therefore to evaluate the efficacy and safety of remdesivir compared with placebo in a randomized double-blind clinical trial.

Can remdesivir speed recovery ?

This study was randomized, double-blind, placebo-controlled, and multicenter. A total of 1,062 hospitalized COVID-19 patients were included. These patients had respiratory involvement requiring hospitalization, including oxygen therapy or more severe respiratory failure.

Participants were divided into two groups: one group received intravenous remdesivir, while the other received a placebo. The primary outcome studied was the time to clinical recovery, defined as sufficient improvement allowing hospital discharge or no longer requiring oxygen or intensive care.

The findings demonstrated that patients treated with remdesivir experienced a shorter recovery time than those receiving placebo. The median recovery time was 10 days in the remdesivir group compared with 15 days in the placebo group, suggesting faster clinical improvement with treatment.

The benefit appeared particularly marked in patients requiring standard oxygen therapy but who had not yet been mechanically ventilated. In contrast, among patients already on mechanical ventilation or in critical condition, the effectiveness of remdesivir appeared much more limited.

The study also showed a trend toward reduced mortality in patients treated with remdesivir. However, this reduction was not statistically significant in the final analysis, meaning the study could not conclusively demonstrate a survival benefit.

Regarding safety, serious adverse events were overall less frequent in the remdesivir group than in the placebo group. The main reported side effects included liver abnormalities, kidney impairment, and gastrointestinal disorders, although the treatment was generally considered well tolerated.

A real but moderate benefit

COVID-19 can progress to severe respiratory forms requiring hospitalization, oxygen therapy, or even mechanical ventilation. The main challenge was to demonstrate that an antiviral could genuinely improve the clinical outcomes of already hospitalized patients and to identify which patients were most likely to benefit.

This study aimed to evaluate the clinical efficacy and safety of remdesivir in hospitalized COVID-19 patients. The findings show that remdesivir modestly accelerates clinical recovery in hospitalized patients with COVID-19, particularly in those requiring oxygen therapy without invasive ventilation. However, its effect on mortality remains uncertain, especially in the most severe cases.

This study was one of the first positive trials involving an antiviral treatment for COVID-19 and contributed to the authorization of remdesivir use in several countries. Future perspectives now focus on identifying the optimal timing of administration, combining remdesivir with other treatments such as anti-inflammatory drugs, and evaluating its effectiveness across different patient profiles with COVID-19.                



 Read next : COVID-19 vaccines linked to longer survival in some cancer patients
 



About the author – Ana Espino
PhD in Immunology, specialized in Virology  
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions